PCSK9-deficiency does not alter blood pressure and sodium balance in mouse models of hypertension

Atherosclerosis

Volumn 239, Issue 1, 2015, Pages 252-259

  Berger, Jean Mathieu ^a   Vaillant, Nathalie ^a   Le May, Cédric ^a   Calderon, Carolina ^a,b   Brégeon, Jeremy ^a   Prieur, Xavier ^a,c   Hadchouel, Juliette ^a,b   Loirand, Gervaise ^a   Cariou, Bertrand ^a,c,d  

^a L INSTITUT DU THORAX   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c UNIVERSITÉ DE NANTES   (France)

^d NANTES UNIVERSITY HOSPITAL   (France)

Author keywords

Angiotensin II; DOCA SALT; ENaC; Natriuresis

Indexed keywords

AMILORIDE; ANGIOTENSIN II; CHLORIDE; DEOXYCORTICOSTERONE ACETATE; EPITHELIAL SODIUM CHANNEL; N(G) NITROARGININE METHYL ESTER; PEPTIDES AND PROTEINS; POTASSIUM ION; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; SODIUM CHLORIDE; SODIUM ION; UNCLASSIFIED DRUG; PCSK9 PROTEIN, HUMAN; SALT INTAKE; SCNN1A PROTEIN, MOUSE; SERINE PROTEINASE; SODIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; ELECTROLYTE BLOOD LEVEL; ELECTROLYTE URINE LEVEL; FEMALE; HYPERTENSION; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PCSK9 MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SODIUM BALANCE; WESTERN BLOTTING; ANIMAL; ARTERY; BLOOD; BLOOD PRESSURE MEASUREMENT; CHEMISTRY; DEFICIENCY; DISEASE MODEL; GENETICS; KIDNEY; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; PHARMACOLOGY; SALT INTAKE; URINE;

AMILORIDE; ANGIOTENSIN II; ANIMALS; ARTERIES; BLOOD PRESSURE; BLOOD PRESSURE DETERMINATION; DISEASE MODELS, ANIMAL; EPITHELIAL SODIUM CHANNELS; FEMALE; HYPERTENSION; KIDNEY; MALE; MICE; MICE, KNOCKOUT; NG-NITROARGININE METHYL ESTER; PROPROTEIN CONVERTASES; SERINE ENDOPEPTIDASES; SODIUM; SODIUM CHLORIDE, DIETARY;

EID: 84921494738     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2015.01.012     Document Type: Article

References (28)

1. Seidah N.G., Benjannet S., Wickham L., Marcinkiewicz J., Jasmin S.B., Stifani S., Basak A., Prat A., Chretien M. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:928-933.
2. Zaid A., Roubtsova A., Essalmani R., Marcinkiewicz J., Chamberland A., Hamelin J., Tremblay M., Jacques H., Din W., Davignon J., et al. Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration. Hepatology 2008, 48:646-654.
3. Costet P., Krempf M., Cariou B. PCSK9 and LDL cholesterol: unravelling the target to design the bullet. Trends Biochem. Sci. 2008, 33:426-434.
4. Horton J.D., Cohen J.C., Hobbs H.H. PCSK9: a convertase that coordinates LDL catabolism. J.Lipid Res. 2009, 50(Suppl.l):S172-S177.
5. Le May C., Kourimate S., Langhi C., Chétiveaux M., Jarry A., Comera C., Collet X., Kuipers F., Krempf M., Cariou B., et al. Proprotein convertase subtilisin kexin type 9 null mice are protected from postprandial triglyceridemia. Arterioscler. Thromb. Vasc. Biol. 2009, 29:684-690.
6. Le May C., Berger J.M., Lespine A., Pillot B., Prieur X., Letessier E., Hussain M.M., Collet X., Cariou B., Costet P. Transintestinal cholesterol excretion is an active metabolic process modulated by PCSK9 and statin involving ABCB1. Arter. Thromb. Vasc. Biol. 2013, 33:1484-1493.
7. Sharotri V., Collier D.M., Olson D.R., Zhou R., Snyder P.M. Regulation of epithelial sodium channel trafficking by proprotein convertase subtilisin/kexin type 9 (PCSK9). J.Biol. Chem. 2012, 287:19266-19274.
8. Soundararajan R., Pearce D., Hughey R.P., Kleyman T.R. Role of epithelial sodium channels and theirs regulators in hypertension. J.Biol. Chem. 2010, 285:30363-30369.
9. Achard J.M., Hadchouel J., Faure S., Jeunemaitre X. Inherited sodium avid states. Adv. Chronic Kidney Dis. 2006, 13:118-123.
10. Meneton P., Jeunemaitre X., de Wardener H.E., MacGregor G.A. Links between dietary salt intake, renal salt handling, blood pressure, and cardiovascular diseases. Physiol. Rev. 2005, 85:679-715.
11. Cariou B., Le May C., Costet P. Clinical aspects of PCSK9. Atherosclerosis 2011, 216:258-265.
12. McKenney J.M., Koren M.J., Kereiakes D.J., Hanotin C., Ferrand A.C., Stein E.A. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J.Am. Coll. Cardiol. 2012, 59:2344-2353.
13. Raal F., Scott R., Somaratne R., Bridges I., Li G., Wasserman S.M., Stein E.A. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the reduction of LDL-C with PCSK9 inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Circulation 2012, 126:2408-2417.
14. Rashid S., Curtis D.E., Garuti R., Anderson N.N., Bashmakov Y., Ho Y.K., Hammer R.E., Moon Y.A., Horton J.D. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:5374-5379.
15. Mills P.A., Huetteman D.A., Brockway B.P., Zwiers L.M., Gelsema A.J., Schwartz R.S., Kramer K. Anew method for measurement of blood pressure, heart rate, and activity in the mouse by radiotelemetry. J.Appl. Phys. 2000, 88:1537-1544.
16. Krege J.H., Hodgin J.B., Hagaman J.R., Smithies O. Anoninvasive computerized tail-cuff system for measuring blood pressure in mice. Hypertension 1995, 25:1111-1115.
17. Picard N., Eladari D., El Moghrabi S., Planes C., Bourgeois S., Houillier P., Wang Q., Burnier M., Deschenes G., Knepper M.A., et al. Defective ENaC processing and function in tissue kallikrein-deficient mice. J.Biol. Chem. 2008, 283:4602-4611.
18. Cariou B., Benoit I., Le May C. Preserved adrenal function in fully PCSK9-deficient subject. Int. J. Cardiol. May. 2014, 176:499-500.
19. Persson L., Henriksson P., Westerlund E., Hovatta O., Angelin B., Rudling M. Endogenous estrogens lower plasma PCSK9 and LDL cholesterol but not Lp(a) or bile acid synthesis in women. Arter. Thromb. Vasc. Biol. 2012, 32:810-814.
20. Roubtsova A., Munkonda M.N., Awan Z., Marcinkiewicz J., Chamberland A., Lazure C., Cianflone K., Seidah N.G., Prat A. Circulating proprotein convertase subtilisin/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue. Arter. Thromb. Vasc. Biol. 2011, 31:785-791.
21. Cohen J.C., Boerwinkle E., Mosley T.H., Hobbs H.H. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N.Engl. J. Med. 2006, 354:1264-1272.
22. Zhao Z., Tuakli-Wosornu Y., Lagace T.A., Kinch L., Grishin N.V., Horton J.D., Cohen J.C., Hobbs H.H. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am. J. Hum. Genet. 2006, 79:514-523.
23. Cariou B., Ouguerram K., Zaïr Y., Guerois R., Langhi C., Kourimate S., Benoit I., Le May C., Gayet C., Belabbas K., et al. PCSK9 dominant negative mutant results in increased LDL catabolic rate and familial hypobetalipoproteinemia. Arterioscler. Thromb. Vasc. Biol. 2009, 29:2191-2197.
24. Lakoski S.G., Lagace T.A., Cohen J.C., Horton J.D., Hobbs H.H. Genetic and metabolic determinants of plasma PCSK9 levels. J.Clin. Endocrinol. Metab. 2009, 94:2537-2543.
25. Cariou B., Le Bras M., Langhi C., Le May C., Guyomarc'h-Delasalle B., Krempf M., Costet P. Association between plasma PCSK9 and gamma-glutamyl transferase levels in diabetic patients. Atherosclerosis 2010, 211:700-702.
26. Werner C., Hoffmann M.M., Winkler K., Böhm M., Laufs U. Risk prediction with proprotein convertase subtilisin/kexin type 9 (PCSK9) in patients with stable coronary disease on statin treatment. Vasc. Pharmacol. 2014, Mar 29, ([Epub ahead of print]). 10.1016/j.vph.2014.03.004.
27. Farnier M. PCSK9 inhibitors. Curr. Opin. Lipidol. 2013, 24:251-258.
28. Blom D.J., Hala T., Bolognese M., Lillestol M.J., Toth P.D., Burgess L., Ceska R., Roth E., Koren M.J., Ballantyne C.M., et al. A52-week placebo-controlled trial of evolucumab in hyperlipidemia. N.Engl. J. Med. 2014, 370:1809-1819.